GlassScriptPhysician profile
Ernesto N Levy
NPI 1760431225
$5,942.17
in general payments reported to CMS, 2019-2025
27 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2022: $109 · 2023: $2,436 · 2024: $2,859 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,218 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,218.02 |
| Education | $187.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $911.25 | 2023-2024 | Saphnelo |
| Amgen INC. | $856.82 | 2019-2024 | Enbrel, Otezla, Krystexxa |
| Lilly USA, LLC | $677.08 | 2023-2025 | Taltz, Olumiant, Zepbound |
| Janssen Biotech, INC. | $600.61 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $570.79 | 2019-2025 | |
| Ucb, INC. | $513.20 | 2019-2024 | Cimzia |
| Abbvie INC. | $491.54 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $236.75 | 2023-2024 | Purified Cortrophin Gel |
| Organon LLC | $171.47 | 2023-2024 | Renflexis, Hadlima |
| Horizon Therapeutics Plc | $166.71 | 2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $118.34 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $79.72 | 2024 | Acthar |
| Pfizer INC. | $74.47 | 2022-2024 | |
| Sandoz INC. | $70.99 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.85 | 2024 | Ofev, Cyltezo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $58.31 | 2023 | Lupkynis |
| Genentech USA, INC. | $52.72 | 2023-2024 | Actemra |
| Genzyme Corporation | $45.19 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $31.78 | 2024 | |
| Tersera Therapeutics LLC | $30.30 | 2019 | |
| Radius Health, INC. | $23.24 | 2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $19.44 | 2024 | Truxima |
| Alexion Pharmaceuticals, INC. | $17.42 | 2024 | Strensiq |
| Exact Sciences Corporation | $16.98 | 2025 | The Cologuard Plus Collection Kit |
| Celltrion USA INC. | $15.79 | 2023 | Yuflyma |
| Octapharma USA, INC. | $14.21 | 2023 | Octagam Immune Globulin (Human) |
| Glaxosmithkline, LLC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.